The Apex Times
Above the Noise
Business Wire
BusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex TimesBusinessEli Lilly to buy Merida Biosciences for $2.88 billion, setting off investor focus on the deal’s strategic fitThe Apex TimesBusinessApple says it has evidence a former employee destroyed material after learning of an investigationThe Apex TimesBusinessTelecom comparison turns on profitability pace versus leverage: AT&T’s margin jump, Verizon’s debt loadThe Apex TimesBusinessAnthropic agrees to a $35 billion cloud computing deal tied to Nvidia-backed Lambda, report saysThe Apex TimesBusinessAMD has tended to fall in September, but market history is only part of the storyThe Apex TimesBusinessDuolingo shares jump after results point to steady user momentum, according to Yahoo FinanceThe Apex TimesBusinessNetflix confirms production of Korean series “Materesa (WT),” led by “Queen of Tears” director and writers behind “The East Palace”The Apex TimesBusinessFTC and 22 States Sue Amazon, Alleging It Secretly Marked Up Ads Shown to Marketplace SellersThe Apex TimesBusinessDeere shares gained as market focused on a jump in profitsThe Apex TimesBusinessBaird lifts Deere to Outperform, citing potential agricultural recovery and raises target to $800The Apex TimesBusinessVenezuela’s energy reopening talks could create upside for Chevron and GE Vernova, but agreements still face major hurdlesThe Apex TimesBusinessTrump Says ExxonMobil Is Preparing to Re-enter Venezuela as Investment Outlook ShiftsThe Apex Times
Back to front
Moderna wins up to 24 million RSV vaccine dose supply deal for Europe, report says
The Apex Times

THE APEX TIMES

Business/The Apex Times/Jul 13, 3:31 PM EDT

Moderna wins up to 24 million RSV vaccine dose supply deal for Europe, report says

The contract is tied to growing demand for protection against respiratory syncytial virus, which can lead to severe lower-respiratory disease. Moderna has not disclosed key terms in the post highlighted by the report, including pricing and delivery timing.

By The Apex Times Newsroom2 min readAI-assisted Apex article

Moderna has secured a contract that could supply up to 24 million doses of an RSV vaccine for customers in Europe, according to a report by Pharmaceutical Technology published July 9.

RSV, or respiratory syncytial virus, is a respiratory pathogen that can cause severe lung illness, particularly in older adults and people with underlying health conditions. The report cites that more than 156,000 adults in Europe are hospitalized each year due to RSV.

The deal described in the report is framed as a supply agreement for as many as 24 million doses, but it does not provide additional operational details such as which countries are covered, the type of delivery commitments, or how the dose volume would scale over time.

No financial terms were included in the cited report, including the total contract value, unit pricing per dose, or whether the figure represents a maximum option with the possibility of reductions based on demand or regulatory uptake.

The vaccine program sits within a broader push to expand respiratory immunization options for adults, where RSV has emerged as a persistent driver of hospital utilization. For companies developing RSV vaccines, securing manufacturing and customer relationships can help convert clinical and commercial momentum into predictable ordering pipelines.

For Moderna, the contract indicates continued commercial execution beyond its core portfolio. The company’s market relevance also hinges on its ability to sustain uptake of its vaccine products across seasons and geographies, especially as multiple manufacturers compete in adult respiratory vaccines.

Still, the report leaves open several questions that investors and health-system buyers would likely want answered before assessing near-term impact. The post highlighted by the report does not specify the contracting entity, the regimen or formulation targeted by the doses, or the delivery schedule and logistics plan.

What to watch next is whether Moderna and the contracting counterpart provide further details through formal announcements, including country coverage, dosing timing, and any updates to dosing forecasts that would influence how the company models future vaccine revenue.

Why It Matters

  • A large potential dose volume suggests demand for adult RSV protection remains high and could support ongoing vaccination programs in Europe.
  • Clear contracting details such as delivery schedules and dosing coverage are typically key inputs for forecasting vaccine revenue and manufacturing planning, but they were not provided in the cited report.
  • RSV competition in adult vaccines can be influenced by distribution relationships and confirmed order volumes, not just clinical performance.
  • If the full 24 million doses are delivered, it could represent a meaningful commercial step for Moderna within respiratory vaccine demand in Europe.

Sources

Key Facts

  • Moderna is reported to have secured a contract for up to 24 million RSV vaccine doses for Europe.
  • The report says RSV can cause severe lung illness and cites hospitalizations among adults in Europe.
  • The report estimates more than 156,000 adult hospitalizations in Europe each year due to RSV.
  • The cited report does not include contract pricing, total deal value, or delivery timing.
  • The report does not identify which specific European customers or countries are covered.

Healthcare Related

Moderna wins up to 24 million RSV vaccine dose supply deal for Europe, report says | The Apex Times